1. Home
  2. HQI vs AGEN Comparison

HQI vs AGEN Comparison

Compare HQI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

HOLD

Current Price

$17.48

Market Cap

233.6M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$8.11

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQI
AGEN
Founded
2002
1994
Country
United States
United States
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.6M
274.8M
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
HQI
AGEN
Price
$17.48
$8.11
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$13.00
$14.50
AVG Volume (30 Days)
21.9K
1.6M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
2.08%
N/A
EPS Growth
73.08
100.00
EPS
0.31
0.96
Revenue
$30,640,000.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
$0.46
N/A
P/E Ratio
$56.29
$8.71
Revenue Growth
N/A
89.95
52 Week Low
$7.38
$2.71
52 Week High
$19.01
$8.85

Technical Indicators

Market Signals
Indicator
HQI
AGEN
Relative Strength Index (RSI) 66.20 61.86
Support Level $10.22 $2.97
Resistance Level $19.01 $8.76
Average True Range (ATR) 1.11 0.59
MACD 0.13 -0.02
Stochastic Oscillator 76.41 77.90

Price Performance

Historical Comparison
HQI
AGEN

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: